Cervical Cancer - Pipeline Review, H1 2018

  • ID: 4540573
  • Report
  • 768 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Abion Inc
  • AVEO Pharmaceuticals Inc
  • Cytori Therapeutics Inc
  • Genexine Inc
  • Juno Therapeutics Inc
  • Oxford Vacmedix UK Ltd
  • MORE
Cervical Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H1 2018, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights:

This latest pipeline guide Cervical Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 3, 37, 39, 1, 45, 8 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 3, 9 and 5 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abion Inc
  • AVEO Pharmaceuticals Inc
  • Cytori Therapeutics Inc
  • Genexine Inc
  • Juno Therapeutics Inc
  • Oxford Vacmedix UK Ltd
  • MORE
Introduction

Cervical Cancer - Overview

Cervical Cancer - Therapeutics Development

Cervical Cancer - Therapeutics Assessment

Cervical Cancer - Companies Involved in Therapeutics Development

Cervical Cancer - Drug Profiles

Cervical Cancer - Dormant Projects

Cervical Cancer - Discontinued Products

Cervical Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Cervical Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cervical Cancer - Pipeline by Abion Inc, H1 2018

Cervical Cancer - Pipeline by Abivax SA, H1 2018

Cervical Cancer - Pipeline by Admedus Ltd, H1 2018

Cervical Cancer - Pipeline by Advaxis Inc, H1 2018

Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Cervical Cancer - Pipeline by Agenus Inc, H1 2018

Cervical Cancer - Pipeline by Amgen Inc, H1 2018

Cervical Cancer - Pipeline by AntiCancer Inc, H1 2018

Cervical Cancer - Pipeline by Antigen Express Inc, H1 2018

Cervical Cancer - Pipeline by ArQule Inc, H1 2018

Cervical Cancer - Pipeline by Asana BioSciences LLC, H1 2018

Cervical Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Cervical Cancer - Pipeline by AstraZeneca Plc, H1 2018

Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Cervical Cancer - Pipeline by Bayer AG, H1 2018

Cervical Cancer - Pipeline by BeiGene Ltd, H1 2018

Cervical Cancer - Pipeline by Bioleaders Corp, H1 2018

Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2018

Cervical Cancer - Pipeline by Blirt SA, H1 2018

Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Cervical Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Cervical Cancer - Pipeline by Cadila Healthcare Ltd, H1 2018

Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H1 2018

Cervical Cancer - Pipeline by Celleron Therapeutics Ltd, H1 2018

Cervical Cancer - Pipeline by Cellestia Biotech AG, H1 2018

Cervical Cancer - Pipeline by Clovis Oncology Inc, H1 2018

Cervical Cancer - Pipeline by Coherus BioSciences Inc, H1 2018

Cervical Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2018

Cervical Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Cervical Cancer - Pipeline by Cytori Therapeutics Inc, H1 2018

Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2018

Cervical Cancer - Pipeline by DelMar Pharmaceuticals Inc, H1 2018

Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018

Cervical Cancer - Pipeline by Eisai Co Ltd, H1 2018

Cervical Cancer - Pipeline by Etubics Corp, H1 2018

Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H1 2018

Cervical Cancer - Pipeline by EyeGene Inc, H1 2018

Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Cervical Cancer - Pipeline by Formation Biologics Inc, H1 2018

Cervical Cancer - Pipeline by Formune SL, H1 2018

List of Figures

Number of Products under Development for Cervical Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abion Inc
  • Abivax SA
  • Admedus Ltd
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Agenus Inc
  • Amgen Inc
  • AntiCancer Inc
  • Antigen Express Inc
  • ArQule Inc
  • Asana BioSciences LLC
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BeiGene Ltd
  • Bioleaders Corp
  • Biomics Biotechnologies Co Ltd
  • Blirt SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • Cancer Research Technology Ltd
  • Celleron Therapeutics Ltd
  • Cellestia Biotech AG
  • Clovis Oncology Inc
  • Coherus BioSciences Inc
  • Corvus Pharmaceuticals Inc
  • Cotinga Pharmaceuticals Inc
  • Cytori Therapeutics Inc
  • CZ BioMed Corp
  • DelMar Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Eisai Co Ltd
  • Etubics Corp
  • Eureka Therapeutics Inc
  • EyeGene Inc
  • F. Hoffmann-La Roche Ltd
  • Formation Biologics Inc
  • Formune SL
  • GamaMabs Pharma SA
  • Gene Techno Science Co Ltd
  • Genentech Inc
  • Genetic Immunity Inc
  • Genexine Inc
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Glycostem Therapeutics BV
  • Glycotope GmbH
  • Gradalis Inc
  • Immunomedics Inc
  • Immunovaccine Inc
  • Innate Pharma SA
  • Iovance Biotherapeutics Inc
  • ISA Pharmaceuticals BV
  • JHL Biotech Inc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kite Pharma Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Molecular Partners AG
  • Mycenax Biotech Inc
  • NeoImmuneTech Inc
  • Novartis AG
  • Ology Bioservices Inc
  • Oncobiologics Inc
  • Ono Pharmaceutical Co Ltd
  • Oxford Vacmedix UK Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Protheragen Inc
  • Puma Biotechnology Inc
  • Regeneron Pharmaceuticals Inc
  • Rexahn Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Samyang Holdings Corp
  • Sanofi
  • Seattle Genetics Inc
  • Selecta Biosciences Inc
  • Shantha Biotechnics Pvt Ltd
  • Sierra Oncology Inc
  • Sirnaomics Inc
  • Sun Pharma Advanced Research Company Ltd
  • Tessa Therapeutics Pte Ltd
  • Theralase Technologies Inc
  • Theravectys SA
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • Vectorite Biomedical Inc
  • Virometix AG
  • VLPbio
  • Zeria Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll